Global Achalasia Cardia Market, By Disease Type (Type I, Type II and Type III), Diagnosis (High Resolution Oesophageal Topography and Endoscopy), Treatment (Botulinum Toxin, Pneumatic Balloon Dilation, Laparoscopic Heller Myotomy), End-Users (Clinics, Hospitals, Diagnostic Centers, Others), Distribution Channel (Direct Tenders, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Achalasia cardia market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.90% in the above-mentioned research forecast period. Introduction of new tools for easy identification of achalasia cardia and rising initiatives by the market players for market expansion.
Moreover, growing awareness for disease symptoms and pipeline drugs also boost the market growth. Technological advancements for disease diagnosis and rising healthcare expenditure act as an opportunity for market growth. But, delayed diagnosis, post-surgical complications and strict regulatory framework may hamper the global achalasia cardia market.
Achalasia cardia is one of the neurodegenerative disorders of the esophagus, which has been reported to affect peristaltic movement and results in impairment of relaxation of the lower oesophageal sphincter. The achalasia cardia pathogenesis is still unknown; however, several studies conducted revealed an autoimmune disorder that triggered the degeneration of myenteric neurons. The high-resolution oesophageal topography and endoscopy can diagnose achalasia cardia. High-resolution manometry is also used for the diagnosis of achalasia cardia. Achalasia cardia is of three types based on the manometric patterns: type I, classic represented by the minimal contractility, type II with panesophageal pressurization, and type III characterized by the spastic distal esophageal contractions. Achalasia cardia can be managed by applying botulinum toxin, pneumatic balloon dilation, laparoscopic Heller myotomy, among others.
The government funding for research and developmental activities related to treatment and diagnosis is increasing and hence expected to provide the market with lucrative growth.
This Achalasia cardia market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Achalasia cardia Market Scope and Market Size
Achalasia cardia market is segmented on the basis of disease type, diagnosis, treatment, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the achalasia cardia market is segmented into Type A, Type B, Type C and Type E.
- On the basis of diagnosis, the achalasia cardia market is segmented into physical examination, skin biopsy, biochemical testing, genetic testing.
- On the basis of treatment, the achalasia cardia market is segmented into miglustat, physical therapy and others.
- On the basis of end-users, the achalasia cardia market is segmented into clinics, hospitals, diagnostic centers, and others.
- On the basis of distribution channel, the achalasia cardia market is segmented into direct tenders, hospital pharmacy, retail pharmacy, online pharmacy and others.
Achalasia cardia Market Country Level Analysis
Achalasia cardia market is analysed and market size information is provided by country, disease type, diagnosis, treatment, end-users and distribution channel as referenced above.
The countries covered in the achalasia cardia market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts for the largest market share due to the increasing research and developmental activities and rising technological advancements. Europe is also expected to grow exponentially due to the rising number of orphan drug designation provided to the drugs by the European Union. Asia-Pacific is expected to account for the largest market share due to increasing government concern for public health and a rise in funding activities for the development of pharmaceutical industries.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Achalasia cardia market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Achalasia cardia Market Share Analysis
Achalasia cardia market competitive landscape provides details by competitor details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to achalasia cardia market.
The major players covered in the achalasia cardia market are Allergan, Ipsen Pharma, Merz Pharma, Medytox, Inc., Lanzhou Institute of Biological Products. Co.Ltd., Revance Therapeutics, Inc., Boston Scientific, Cook, Cardinal Health, Medical Devices Business Services, Inc., Hospiinz, Surgical Innovations, Evolus, Inc., Medorah Meditek Pvt. Ltd., STERIS, PENTAX Medical, XION GmbH, Aohua Endoscopy Co., Ltd., Laborie, Inc., Sumitomo Bakelite Co., Ltd., Medtronic, PENTAX Medical among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.